Acute Coronary Syndrome, Stable Angina
Conditions
Brief summary
Coronary artery disease (including stable angina and acute coronary disease) remains the leading mortality and morbidity worldwide. Improvement in biomarker, imaging research have led to new predictors for the prognosis, which may have great clinical value in the current era of personalized medicine. However, there is no available biomarker-based prediction rule for risk assessment of adverse events in patients with stable angina and acute coronary disease. Therefore, we aim to develop and validate a new biomarker-based risk model to improve the prognostication of adverse events (e.g. ischemic and bleeding events ) in the patient population.
Detailed description
Patients enrolled in Qilu Hospital of Shandong University (Jinan, China), Chinese PLA General Hospital Hospital (Beijing, China) and Peking University First Hospital (Beijing, China) are designed as the development cohort to derive the risk prediction models of ischemic and bleeding events. Patients enrolled in Peking University Third Hospital ( Beijing, China) Zibo Central hospital (Zibo, China) are designed as the independent validation cohort.
Interventions
BIOLOGICALPlasma biomarker
New emerging plasma biomarkers carrying prognositic information
Sponsors
Peking University Third Hospital
Chinese PLA General Hospital Hospital
Peking University First Hospital
Central Hospital of Zibo
Qilu Hospital of Shandong University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Hospitalized patients with the diagnosis of any type of coronary artery disease (stable angina, unstable angina, non ST-segment elevation myocardial infarction or ST-segment elevation myocardial infarction) 2. Age ≥18 years of age and \<85 years of age 3. Patient or guardian provided informed written consent
Exclusion criteria
1. Prior surgery (cardiac or non-cardiac), trauma or clinically evident coagulopathic bleeding (e.g. gastrointestinal, genitourinary, et al) 2. Patient with non-cardiac co-morbidities with life expectancy less than 12 months 3. Patients unwilling or unable to comply with all clinical follow-up schedules at 30 days, 6 months and 12 months after discharge
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Major Adverse Cardiac Events | 12 months | a composite of cardiac death, myocardial infarction or stroke |
| Major bleeding | 12 months | BARC 3 or more bleeding |
Countries
China
Contacts
Primary ContactYuguo Chen, MD,PhD
Outcome results
None listed